St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral doses

Pharmazie

Volumn 63, Issue 4, 2008, Pages 296-302

  Paulke, A ^a   Noldner M ^b   Schubert Zsilavecz, M ^a   Wurglics, Mario ^a  

^a GOETHE UNIVERSITY   (Germany)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; ISOQUERCITRIN; ISORHAMNETIN; QUERCETIN; RUTOSIDE; TAMARIXETIN; UNCLASSIFIED DRUG; WS 5572;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FORCED SWIMMING TEST; MALE; MULTIPLE DRUG DOSE; NONHUMAN; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; BRAIN; DISACCHARIDES; FLAVONOIDS; FLAVONOLS; HYPERICUM; MALE; PLANT EXTRACTS; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 42149105621     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.7751     Document Type: Article

References (33)

1. Bhattacharya SK, Chakrabarti A, Chatterjee SS (1998) Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry 31 Suppl 1: 22-29.
2. Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H (2003) Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci 73: 627-639.
3. Butterweck V, Jurgenliemk G, Nahrstedt A, Winterhoff H (2000) Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 66: 3-6.
4. Butterweck V, Korte B, Winterhoff H (2001) Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 34 Suppl 1: S2-S7.
5. Butterweck V, Lieflander-Wulf U, Winterhoff H, Nahrstedt A (2003) Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats. Planta Med 69: 189-192.
6. Butterweck V, Nahrstedt A, Evans J, Hufeisen S, Rauser L, Savage J, Popadaj B, Ernsberger P, Roth BL (2002) In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl) 162: 193-202.
7. Cermak R, Landgraf S, Wolffram S (2003) The bioavailability of quercetin in pigs depends on the glycoside moiety and on dietary factors. J Nutr 133: 2802-2807.
8. Day AJ, Mellon F, Barron D, Sarrazin G, Morgan MR, Williamson G (2001) Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radical Res 35: 941-952.
9. Erlund I, Alfthan G, Siren H, Ariniemi K, Aro A (1999) Validated method for the quantitation of quercetin from human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B, Biomed Sci Appl 727: 179-189.
10. Erlund I, Kosonen T, Alfthan G, Maenpää J, Pertunen K, Kenraali J, Parantainen J, Aro A (2000) Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56:545-553.
11. Gobbi M, Moia M, Pirona L, Morizzoni P, Pennini T (2001) In vitro binding studies with two hypericum perforatum extracts-hyperforin, hypericin and biapigenin-on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 34 Suppl 1: S45-S48.
12. Gobbi M, Valle FD, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, Caccia S, Cervo L, Pennini T (1999) Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Schmiedebergs Arch Pharmacol 360: 262-269.
13. Graefe EU, Derendorf H, Veit M (1999) Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int J Clin Pharmacol Therap 37: 219-233.
14. Graefe EU, Wittig J, Mueller S, Riethling AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M (2001) Pharmacokinetics and bioavailability of quercetin glycosides in humans. J Clin Pharmacol 41: 492-499.
15. Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997) Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19-29.
16. Linde K, Berner M, Egger M, et al. (2005) St John's wort for depression: meta-analysis of randomised controlled trials. Br J Psychiatry 186: 99-107.
17. Manach C, Morand C, Demigné C, Texier O, Régérat F, Rémésy C (1997) Bioavailability of rutin and quercetin in rats. FEBS Lett 409: 12-16.
18. Müller WE, Rolli M, Schafer C, Hafner U (1997) Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 30 Suppl 2: 102-107.
19. Müller WE, Singer A, Wonnemann M (2001) Hyperforin-antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34 Suppl 1: S98-102.
20. NöTdner M (2001) Antidepressive Effekte von Johanniskrautextrakt und wichtigen Inhaltsstoffen im Tiermodell. In: Müller WE, Gastpar, M. (ed) Behandlung von depressiven Patienten in der täglichen Praxis, vol. LinguaMed Verlags-GmbH, Neu-Isenburg, p 31
21. Nöldner M, Schötz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 68: 577-580.
22. O'Leary KA, Day AJ, Needs PW, Mellin FA, O'Brien NM, Williamson G (2003) Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65: 479-491.
23. Paulke A, Schubert-Zsilavecz M, Wurglics M (2006) Determination of St. John's wort flavonoid-metabolites in rat brain through high performance liquid chromatography coupled with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 832: 109-113.
24. Porsolt R D (1979) Animal model of depression. Biomedicine 30: 139-140.
25. Roz N, Rehavi M (2003) Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci 73: 461-470.
26. Schulte-Löbbert S, Holoubek G, Müller WE, Schubert-Zsilavecz M, Wurglics M (2004) Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products. J Pharm Pharmacol 56: 813-818.
27. Schulz HU, Schurer M, Bassler D, Weiser D (2005) Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneim.-Forsch 55: 15-22.
28. Schwabe U, Paffrath D (2004) Arzneiverordnungs-Report 2003. Springer-Verlag Berlin, Heidelberg, New York.
29. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Experim Therap 290: 1363-1368.
30. Singh A, Naidu PS, Kulkarni SK (2003) Quercetin potentiates L-dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. Pharmacology 68: 81-88.
31. Wittig J, Herderich M, Graefe EU, Veit M (2001) Identification of quercetin glucuronides in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 753: 237-243.
32. Wonnemann M, Singer A, Müller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23: 188-197.
33. Wurglics M, Schubert-Zsilavecz M (2006) Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45: 449-468.